Larimar Therapeutics
LRMR
103 hedge funds and large institutions have $132M invested in Larimar Therapeutics in 2025 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 32 increasing their positions, 33 reducing their positions, and 28 closing their positions.
26% more call options, than puts
Call options by funds: $229K | Put options by funds: $182K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 33
4.41% less ownership
Funds ownership: 99.41% → 95% (-4.4%)
11% less funds holding
Funds holding: 116 → 103 (-13)
46% less capital invested
Capital invested by funds: $245M → $132M (-$114M)
46% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$6.05M |
| 2 |
Renaissance Technologies
New York
|
+$1.46M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.45M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$1.37M |
| 5 |
Millennium Management
New York
|
+$1.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$8.13M |
| 2 |
Goldman Sachs
New York
|
-$4.68M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$2.89M |
| 4 |
FAM
Fred Alger Management
New York
|
-$2.85M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$2.75M |
LRMR Hedge Fund Activity: Q1 2025 in Review
103 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q1 2025, worth a combined $132M — down 46% from $245M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of LRMR and 15 opened new positions — a net loss of 13 holders — while 33 trimmed existing stakes and 32 added.
The largest buyer was Opaleye Management, opening a new position worth an estimated $6.05M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $8.13M sold.
- 103 institutional investors held Larimar Therapeutics (LRMR) as of Q1 2025, down from 116 in Q4 2024.
- Funds reported $132M of Larimar Therapeutics stock for Q1 2025, down 46% quarter-over-quarter.
- 15 funds opened new Larimar Therapeutics positions in Q1 2025 and 28 closed out, a net change of -13 holders.
- The largest Larimar Therapeutics buyer in Q1 2025 was Opaleye Management, an estimated $6.05M added.
- The largest Larimar Therapeutics seller in Q1 2025 was Adage Capital Partners, an estimated $8.13M sold.
Based on aggregated 13F filings for Q1 2025.